Literature DB >> 2970295

Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells.

R L Sutherland1, R E Hall, G Y Pang, E A Musgrove, C L Clarke.   

Abstract

The effect of medroxyprogesterone acetate (MPA) on breast cancer cell proliferation kinetics was investigated in ten human breast cell lines growing as monolayer cultures. Significant inhibition of growth occurred only in the estrogen receptor-positive, progesterone receptor-positive cell lines, T-47D, MCF-7, ZR 75-1, BT 474, and MDA-MB-361. Among these cell lines sensitivity to MPA varied widely; concentrations required for 20% inhibition of growth ranged from 0.04 nM for T-47D to greater than 100 nM for ZR 75-1 cells. Furthermore, although the most sensitive line, T-47D, had the highest level of PR, sensitivity to MPA was not correlated with PR levels among the responsive cell lines. More detailed studies were undertaken with the T-47D cell line. The growth-inhibitory response was confined to the progestins: MPA, ORG 2058, R5020, and progesterone, while androgens, estrogens, and glucocorticoids were without effect over the same concentration range (0.1-100 nM). MPA-induced growth inhibition was associated with a significant decrease in the proportion of S-phase cells with an accumulation of cells in the G0-G1 phase of the cell cycle. Cells began to accumulate in G0-G1 after 12 h of drug treatment and the effect was maximal by 24 h, i.e., maximal effects were observed during the first cell cycle following drug treatment. By contrast, significant accumulation in G0-G1 required exposure of MCF-7 cells to MPA for at least two cell cycle times, i.e., 48 h and the effect was still increasing at 96 h. Stathmokinetic studies revealed that in both cell lines accumulation in the G0-G1 phase was due to an MPA-induced increase in the G1 transit time. These data indicate that MPA and other progestins have direct growth inhibitory effects on estrogen receptor-positive and progesterone receptor-positive human breast cancer cells in vitro and these effects can be accounted for by a decrease in the rate at which cells traverse the G1 phase of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2970295

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Down-regulation of androgen receptor by progestins and interference with estrogenic or androgenic stimulation of mammary carcinoma cell growth.

Authors:  R Hackenberg; J Hofmann; G Wolff; F Hölzel; K D Schulz
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  Multiple actions of synthetic 'progestins' on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids.

Authors:  R Poulin; D Baker; D Poirier; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1991 Jan-Feb       Impact factor: 4.872

3.  Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes.

Authors:  E A Musgrove; C S Lee; R L Sutherland
Journal:  Mol Cell Biol       Date:  1991-10       Impact factor: 4.272

4.  Description of a new human breast cancer cell line, IIB-BR-G, established from a primary undifferentiated tumor.

Authors:  L Bover; M Barrio; I Slavutsky; A I Bravo; C Quintans; A Bagnăti; B Lema; J Schiaffi; R Yomha; J Mordoh
Journal:  Breast Cancer Res Treat       Date:  1991-09       Impact factor: 4.872

Review 5.  Deciphering the divergent roles of progestogens in breast cancer.

Authors:  Jason S Carroll; Theresa E Hickey; Gerard A Tarulli; Michael Williams; Wayne D Tilley
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

6.  Effects of antiprogestins on the rate of proliferation of breast cancer cells.

Authors:  K Iwasaki; B Underwood; M Herman; S Dinda; S Kodali; H J Kloosterboer; C Hurd; V K Moudgil
Journal:  Mol Cell Biochem       Date:  1999-08       Impact factor: 3.396

7.  Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression.

Authors:  E A Musgrove; J A Hamilton; C S Lee; K J Sweeney; C K Watts; R L Sutherland
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

8.  Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor.

Authors:  R Hackenberg; T Hawighorst; A Filmer; A H Nia; K D Schulz
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle.

Authors:  E A Musgrove; C S Lee; M F Buckley; R L Sutherland
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

Review 10.  Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use.

Authors:  G R Jang; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1997-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.